Literature DB >> 23995612

Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients.

José Luis Piñana1, Pau Montesinos, Rodrigo Martino, Lourdes Vazquez, Montserrat Rovira, Javier López, Montserrat Batlle, Ángela Figuera, Pere Barba, Juan José Lahuerta, Guillermo Debén, Cristina Perez-Lopez, Raimundo García, Pedro Rosique, Esperanza Lavilla, Adriana Gascón, David Martínez-Cuadrón, Miguel Ángel Sanz.   

Abstract

Bacteremia is the most frequent infectious complication during neutropenia in patients receiving autologous hematopoietic stem cell transplantation (ASCT). The objective of this study was to analyze the incidence, characteristics, risk factors, and outcome of bacteremia during the early period after ASCT. A total of 720 patients undergoing ASCT in two observational prospective consecutive multicenter studies of the Programa Español para el Tratamiento de las Hemopatías group were analyzed. Bacteremia occurred in 20 % of patients. Coagulase-negative Staphylococcus was the most frequent (66 %) among the gram-positive agents and Escherichia coli (49 %) among the gram-negative agents. Multivariate analysis showed that the length of neutropenia <1 × 10(9)/L (more than 9 days) [relative risk (RR) of 2.6, p < 0.001] was the sole risk factor for overall bacteremia. We identified the length of neutropenia <1 × 10(9)/L (more than 9 days) (RR 4.98, p < 0.001) and the use of prophylactic fluoroquinolones (RR 0.46, p < 0.01) as specific risk factors for gram-negative bacteremia. Risk factors for gram-positive bacteremia were the use of total parenteral nutrition (RR 1.92, p < 0.01) and deep neutropenia (<0.1 × 10(9)/L), with duration over 5 days (RR 1.67, p < 0.027). Bacteremia showed an increased morbidity with no impact on neither overall nor infectious related mortality. The identification of such risk factors may be helpful to implement prophylactic and therapeutic risk-adapted strategies to reduce the incidence of bacteremia in ASCT.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23995612     DOI: 10.1007/s00277-013-1872-4

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  14 in total

1.  Risk factor for death in hematopoietic stem cell transplantation: are biomarkers useful to foresee the prognosis in this population of patients?

Authors:  K S R Massaro; R Macedo; B S de Castro; F Dulley; M S Oliveira; M A S Yasuda; A S Levin; S F Costa
Journal:  Infection       Date:  2014-09-30       Impact factor: 3.553

2.  Fluoroquinolone prophylaxis in autologous hematopoietic stem cell transplant recipients.

Authors:  Dipenkumar Modi; Hyejeong Jang; Seongho Kim; Malini Surapaneni; Kamya Sankar; Abhinav Deol; Lois Ayash; Divaya Bhutani; Lawrence G Lum; Voravit Ratanatharathorn; Richard Manasa; Kendra Mellert; Pranatharthi Chandrasekar; Joseph P Uberti
Journal:  Support Care Cancer       Date:  2017-04-02       Impact factor: 3.603

3.  Bacteraemia post-autologous haematopoietic stem cell transplantation in the absence of antibacterial prophylaxis: a decade's experience from Lebanon.

Authors:  Rima Moghnieh; Dania Abdallah; Lyn Awad; Tamima Jisr; Anas Mugharbil; Ali Youssef; Hani Tamim; Samer Khaldieh; Oula Massri; Najat Rashini; Youssef Hamdan; Ahmad Ibrahim
Journal:  Infection       Date:  2018-08-24       Impact factor: 3.553

Review 4.  Bloodstream infections in neutropenic cancer patients: A practical update.

Authors:  Giulia Gustinetti; Malgorzata Mikulska
Journal:  Virulence       Date:  2016-04-02       Impact factor: 5.882

Review 5.  Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma.

Authors:  M Martino; R M Lemoli; C Girmenia; L Castagna; B Bruno; F Cavallo; M Offidani; I Scortechini; M Montanari; G Milone; L Postacchini; A Olivieri
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

6.  Infections in Hematopoietic Cell Transplant Recipients: Results From the Organ Transplant Infection Project, a Multicenter, Prospective, Cohort Study.

Authors:  Mindy G Schuster; Angela A Cleveland; Erik R Dubberke; Carol A Kauffman; Robin K Avery; Shahid Husain; David L Paterson; Fernanda P Silveira; Tom M Chiller; Kaitlin Benedict; Kathleen Murphy; Peter G Pappas
Journal:  Open Forum Infect Dis       Date:  2017-03-22       Impact factor: 3.835

7.  Bacteremia in pediatric patients with hematopoietic stem cell transplantation.

Authors:  Paola Perez; Jaime Patiño; Mayra Estacio; Jessica Pino; Eliana Manzi; Diego Medina
Journal:  Hematol Transfus Cell Ther       Date:  2019-08-11

8.  Infectious Complications during Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Children with High-Risk or Recurrent Solid Tumors.

Authors:  Young Bae Choi; Eun Sang Yi; Ji-Man Kang; Ji Won Lee; Keon Hee Yoo; Yae-Jean Kim; Ki Woong Sung; Hong Hoe Koo
Journal:  PLoS One       Date:  2016-09-14       Impact factor: 3.240

9. 

Authors:  Hans-Jürgen Laws; Ulrich Baumann; Christian Bogdan; Gerd Burchard; Maximilian Christopeit; Jane Hecht; Ulrich Heininger; Inken Hilgendorf; Winfried Kern; Kerstin Kling; Guido Kobbe; Wiebe Külper; Thomas Lehrnbecher; Roland Meisel; Arne Simon; Andrew Ullmann; Maike de Wit; Fred Zepp
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2020-05       Impact factor: 1.513

10.  The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever.

Authors:  Luis-Gerardo Rodríguez-Lobato; Alexandra Martínez-Roca; Sandra Castaño-Díez; Alicia Palomino-Mosquera; Gonzalo Gutiérrez-García; Alexandra Pedraza; María Suárez-Lledó; Montserrat Rovira; Carmen Martínez; Carlos Fernández de Larrea; María-Teresa Cibeira; Laura Rosiñol; Ester Lozano; Pedro Marín; Joan Cid; Miquel Lozano; Ana Belén Moreno-Castaño; Marta Palomo; Maribel Díaz-Ricart; Cristina Gallego; Adelina Hernando; Susana Segura; Enric Carreras; Álvaro Urbano-Ispizua; Joan Bladé; Francesc Fernández-Avilés
Journal:  PLoS One       Date:  2020-11-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.